Repeat FNA for risk stratification of atypia of undetermined significance in thyroid nodules: A population‐based cohort without molecular testing
BACKGROUND: Atypia of undetermined significance (AUS; Bethesda category III) is a heterogeneous thyroid fine-needle aspiration (FNA) category with variable malignancy risk. Molecular testing guides AUS management in North America but is unavailable or cost-prohibitive in much of the world. This study evaluated repeat FNA as primary AUS triage and the contribution of cytomorphologic subclassification in a population-based cohort without molecular testing. METHODS: The authors identified all AUS thyroid FNAs in the Fraser Health Authority, British Columbia (2014-2019), with follow-up through 2022. Index cytology was subclassified by architectural, morphologic/nuclear, and oncocytic atypia. Repeat-FNA outcomes, surgical pathology, and clinical/radiologic data were correlated; noninvasive follicular thyroid neoplasm with papillary-like nuclear features was classified as nonmalignant. RESULTS: Among 611 AUS nodules, 271 (44.4%) underwent repeat FNA and 237 (38.8%) resection. Resection-based risk of malignancy (ROM) was 32.9% (78 of 237); minimum observed malignancy was 12.8% (78 of 611). The second FNA was benign in 116 (42.8%), persistent AUS in 78 (28.8%), nondiagnostic in 58 (21.4%), and upgraded in 19 (7.0%). Minimum observed malignancy was 2.6% (3 of 116) after a benign versus 47.4% (9 of 19) after an upgraded second FNA. A benign repeat FNA obviated surgery in 103 of 116 (88.8%). AUS-nuclear carried a higher ROM than AUS-other (38.6% vs. 21.5%; p = .008; adjusted odds ratio, 2.33; 95% CI, 1.24-4.38) but did not predict repeat-FNA outcome (p = .420). CONCLUSIONS: In a molecular-testing-free, population-based cohort, repeat FNA effectively triaged AUS: benign resolution was frequent and marked very low malignancy risk, whereas persistent or upgraded cytology selected nodules for surgery. Cytomorphologic subclassification provided complementary risk stratification, supporting repeat FNA as cost-effective first-line management where molecular testing is unavailable.
Authors
- Reza Alaghehbandan (ORCID: https://orcid.org/0000-0002-6708-5032)
- Neha Khaitan
- Christopher C Griffith (ORCID: https://orcid.org/0000-0002-4407-6555)
- Lara Maria Stričak
- Khashayar Saybani (ORCID: https://orcid.org/0009-0006-6071-6475)
- Paria Sokhanran
- Karolina Oscilowicz
- Ghazal Sokhanran
- Anita Zamanigohar
- Aland Barzinjy
- Jaleh Esmaeeli
- Yung‐Fang Tu
Institutions
- Cleveland Clinic (US)
- Royal Columbian Hospital (CA)
- University of British Columbia (CA)
- Henry Ford Health System (US)
- Simon Fraser University (CA)
- University of Zagreb (HR)
- New Cross Hospital (GB)
- Henry Ford Hospital (US)
- Wojewódzki Szpital Specjalistyczny we Wrocławiu (PL)
- The Royal Wolverhampton NHS Trust (GB)
Publication Details
- Journal
- Cancer Cytopathology
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1002/cncy.70171
- Primary Topic
- Thyroid Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00